140 related articles for article (PubMed ID: 33511942)
21. Macrophages induce resistance to 5-fluorouracil chemotherapy in colorectal cancer through the release of putrescine.
Zhang X; Chen Y; Hao L; Hou A; Chen X; Li Y; Wang R; Luo P; Ruan Z; Ou J; Shi C; Miao H; Liang H
Cancer Lett; 2016 Oct; 381(2):305-13. PubMed ID: 27514455
[TBL] [Abstract][Full Text] [Related]
22. Circ_0007031 enhances tumor progression and promotes 5-fluorouracil resistance in colorectal cancer through regulating miR-133b/ABCC5 axis.
He X; Ma J; Zhang M; Cui J; Yang H
Cancer Biomark; 2020; 29(4):531-542. PubMed ID: 32865180
[TBL] [Abstract][Full Text] [Related]
23. Resistance of colon cancer to 5-fluorouracil may be overcome by combination with chloroquine, an in vivo study.
Sasaki K; Tsuno NH; Sunami E; Kawai K; Hongo K; Hiyoshi M; Kaneko M; Murono K; Tada N; Nirei T; Takahashi K; Kitayama J
Anticancer Drugs; 2012 Aug; 23(7):675-82. PubMed ID: 22561420
[TBL] [Abstract][Full Text] [Related]
24. Esculetin enhances the inhibitory effect of 5-Fluorouracil on the proliferation, migration and epithelial-mesenchymal transition of colorectal cancer.
Yan L; Yu HH; Liu YS; Wang YS; Zhao WH
Cancer Biomark; 2019; 24(2):231-240. PubMed ID: 30689555
[TBL] [Abstract][Full Text] [Related]
25. Upregulation of microRNA-135b and microRNA-182 promotes chemoresistance of colorectal cancer by targeting ST6GALNAC2 via PI3K/AKT pathway.
Liu B; Liu Y; Zhao L; Pan Y; Shan Y; Li Y; Jia L
Mol Carcinog; 2017 Dec; 56(12):2669-2680. PubMed ID: 28767179
[TBL] [Abstract][Full Text] [Related]
26. 5-Fluorouracil inhibits cell migration by induction of Sestrin2 in colon cancer cells.
Seo K; Ki SH; Park EY; Shin SM
Arch Pharm Res; 2017 Feb; 40(2):231-239. PubMed ID: 28028695
[TBL] [Abstract][Full Text] [Related]
27. Novel 5-fluorouracil sensitizers for colorectal cancer therapy: Design and synthesis of S1P receptor 2 (S1PR2) antagonists.
Luo D; Guo Z; Zhao X; Wu L; Liu X; Zhang Y; Zhang Y; Deng Z; Qu X; Cui S; Wan S
Eur J Med Chem; 2022 Jan; 227():113923. PubMed ID: 34688013
[TBL] [Abstract][Full Text] [Related]
28. Dihydroartemisinin potentiates antitumor activity of 5-fluorouracil against a resistant colorectal cancer cell line.
Yao Z; Bhandari A; Wang Y; Pan Y; Yang F; Chen R; Xia E; Wang O
Biochem Biophys Res Commun; 2018 Jun; 501(3):636-642. PubMed ID: 29738772
[TBL] [Abstract][Full Text] [Related]
29. CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer.
Delhorme JB; Bersuder E; Terciolo C; Vlami O; Chenard MP; Martin E; Rohr S; Brigand C; Duluc I; Freund JN; Gross I
Biomed Pharmacother; 2022 Mar; 147():112630. PubMed ID: 35051860
[TBL] [Abstract][Full Text] [Related]
30. Combined 5-FU and ChoKα inhibitors as a new alternative therapy of colorectal cancer: evidence in human tumor-derived cell lines and mouse xenografts.
de la Cueva A; Ramírez de Molina A; Alvarez-Ayerza N; Ramos MA; Cebrián A; Del Pulgar TG; Lacal JC
PLoS One; 2013; 8(6):e64961. PubMed ID: 23762272
[TBL] [Abstract][Full Text] [Related]
31. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
[TBL] [Abstract][Full Text] [Related]
32. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
Chian S; Li YY; Wang XJ; Tang XW
Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
[TBL] [Abstract][Full Text] [Related]
33. Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.
Nita ME; Tominaga O; Nagawa H; Tsuruo T; Muto T
Hepatogastroenterology; 1998; 45(24):2117-22. PubMed ID: 9951876
[TBL] [Abstract][Full Text] [Related]
34. Effect of Thymidine Phosphorylase Gene Demethylation on Sensitivity to 5-Fluorouracil in Colorectal Cancer Cells.
Koyama M; Osada E; Akiyama N; Eto K; Manome Y
Anticancer Res; 2022 Feb; 42(2):837-844. PubMed ID: 35093881
[TBL] [Abstract][Full Text] [Related]
35. MiR-519d reduces the 5-fluorouracil resistance in colorectal cancer cells by down-regulating the expression of CCND1.
Huang R; Lin JY; Chi YJ
Eur Rev Med Pharmacol Sci; 2018 May; 22(9):2869-2875. PubMed ID: 29771440
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of miR-215-3p sensitizes colorectal cancer to 5-fluorouracil induced apoptosis through regulating CXCR1.
Li XW; Qiu SJ; Zhang X
Eur Rev Med Pharmacol Sci; 2018 Nov; 22(21):7240-7250. PubMed ID: 30468467
[TBL] [Abstract][Full Text] [Related]
37. STAT5a-targeting miRNA enhances chemosensitivity to cisplatin and 5-fluorouracil in human colorectal cancer cells.
Hong X; Chen G; Wang M; Lou C; Mao Y; Li Z; Zhang Y
Mol Med Rep; 2012 May; 5(5):1215-9. PubMed ID: 22367509
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells.
Inaba M; Naoe Y; Mitsuhashi J
Biol Pharm Bull; 1998 Jun; 21(6):569-73. PubMed ID: 9657039
[TBL] [Abstract][Full Text] [Related]
39. Design, synthesis and biological evaluation of sphingosine-1-phosphate receptor 2 antagonists as potent 5-FU-resistance reversal agents for the treatment of colorectal cancer.
Luo D; Zhang Y; Yang S; Tian X; Lv Y; Guo Z; Liu X; Han G; Liu S; Wang W; Cui S; Qu X; Wan S
Eur J Med Chem; 2021 Dec; 225():113775. PubMed ID: 34411894
[TBL] [Abstract][Full Text] [Related]
40. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
Du C; Huang D; Peng Y; Yao Y; Zhao Y; Yang Y; Wang H; Cao L; Zhu WG; Gu J
Cancer Lett; 2017 Aug; 400():183-193. PubMed ID: 28465257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
